Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.65 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 4/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932715 | 0.91 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9932672 | 0.90 | BRAF (0.54) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9933461 | 0.90 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9932383 | 0.90 | BRAF (0.59) | BRAFCCR4AURKARPS6KB1MAPK1 | |
| SCHEMBL9932228 | 0.88 | BRAF (0.67) | BRAFCCR4MAPK1 | |
| SCHEMBL9933204 | 0.86 | BRAF (0.73) | BRAFCCR4MAPK1 | |
| SCHEMBL9932910 | 0.85 | BRAF (0.47) | BRAFAURKARPS6KB1PDPK1AURKB | |
| SCHEMBL9932720 | 0.84 | BRAF (0.62) | BRAFCCR4MAPK1 | |
| SCHEMBL9932385 | 0.82 | BRAF (0.60) | BRAFCCR4MAPK1 | |
| SCHEMBL9967958 | 0.81 | BRAF (0.89) | BRAFCCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885CCR4 3948/4885AURKA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.